A clinical trial involving 1,200 adults evaluated the safety of standardised ashwagandha root extract. Participants took either ashwagandha or a placebo for 24 weeks without adverse effects on liver or kidney function. The study monitored participants' immune responses following COVISHIELD vaccination. Results indicated that ashwagandha did not impact virus-neutralising activity compared to the placebo group. This trial adds to the evidence supporting the safety of Ayurveda interventions.
RSS News
Economic times
0 thoughts on “Ashwagandha’s 24-week safety test brings reassuring findings: Report”
Leave a Reply
Your email address will not be published. Required fields are marked *
RECENT NEWS
- Pralay: Kalyani Priyadarshan shifts to Mumbai, trains for Ranveer Singh starrer
- Shanoo post sparks debate: Casting director’s ‘talent’ note divides actors
- Aishwarya Rai Bachchan tells paps to get together for a group photo
- Rajinikanth surprises fans by arriving at ‘Dharmam’ shoot in an auto-rickshaw
- Centre agrees to procure sunflower, green gram, and soyabean crops at MSP in Karnataka
